

EudraCT number 2014-002683-32

Sponsor code: DUR001-305

Study Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia

Please note the following: Although a EudraCT number was assigned for this trial, the study was prematurely terminated (not initiated). Therefore, AbbVie will not be submitting study results.